AMAZON-PRIME-VIDEO
1.7.2021 17:37:14 CEST | Business Wire | Press release
Amazon Prime Video today announced the exclusive global premiere (outside of Japan) of the highly anticipated Japanese anime blockbuster EVANGELION:3.0+1.01 THRICE UPON A TIME on August 13th . EVANGELION:3.0+1.01 THRICE UPON A TIME is the fourth and final chapter of the new theatrical edition of Evangelion . The anime film – which is the highest-grossing in all movies by chief director Hideaki Anno and most-watched movie in Japanese theatres in 2021- is from directors Kazuya Tsurumaki , Katsuichi Nakayama and Mahiro Maeda as well as legendary creator, screenwriter and chief director Hideaki Anno (Shin Godzilla ). To celebrate the finale of the franchise, Prime Video will also release the three previous movies, EVANGELION:1.11 YOU ARE (NOT) ALONE., EVANGELION:2.22 YOU CAN (NOT) ADVANCE., EVANGELION:3.33 YOU CAN (NOT) REDO. to fans in more than 240 countries and territories.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005692/en/
The blockbuster franchise is a Japanese anime pop culture phenomenon based on the story of Evangelion, an artificial human and multipurpose humanoid weapon, and the Angels, an unknown life-form which takes place after the Earth has been shattered by a cataclysmic event. The film features all original voice actors including Megumi Ogata , Megumi Hayashibara , Yûko Miyamura and uses the latest imaging technology to showcase the personalities and relationships of its unique characters as they fight for survival. It will be dubbed in 10 languages including English, French, German, Portuguese, Spanish and Italian, and offer subtitles in 28 languages.
Since the TV series first aired in 1995, the Evangelion franchise has had a significant impact on Japanese pop culture and has elevated the anime genre worldwide. The legendary anime franchise was then reborn as a new movie series Evangelion: New Theatrical Edition in 2007 and this fourth and final movie released across theatres in Japan in March has gone on to break records, both for Hideaki Anno’s films and also as Japan’s most-watched theatrical movie of the year. EVANGELION:3.0+1.01 THRICE UPON A TIME on Amazon Prime Video will be the latest version of the film which includes revised scenes and is releasing across theatres now in Japan.
“The EVANGELION films have been thrilling fans for years and we know that there is a huge appetite around the world for the finale,” said Brad Beale, Vice President, Worldwide Content Licensing Prime Video. “I’m excited for Prime members worldwide to finally have the opportunity to watch the anime masterpiece EVANGELION:3.0+1.01 THRICE UPON A TIME, as well as the three previous films.”
“I’d like to thank every Eva fan in the world for your continued support,” said Hideaki Anno, Creator, Screenwriter and Chief Director. “We were looking for the best way to offer the movie to fans overseas as early as possible in a challenging situation with movie theatres during COVID-19, and are happy to have found Prime Video as a partner to stream it globally. We highly recommend watching it on a big TV screen for the best viewing experience.”
ABOUT
EVANGELION:3.0+1.01 THRICE UPON A TIME
The fourth and final installment of the Rebuild of Evangelion. Misato and her anti-Nerv group Wille arrive in Paris, a city now red from core-ization. Crew from the flagship Wunder land on a containment tower. They only have 720 seconds to restore the city. When a horde of Nerv Evas appear, Mari’s improved Eva Unit 8 must intercept. Meanwhile, Shinji, Asuka, and Rei (provisional name) wander around Japan.
Studio: khara, Inc.
Chief director: Hideaki Anno
, Director: Kazuya Tsurumaki
, Katsuichi Nakayama
and Mahiro Maeda
, Screenwriter: Hideaki Anno
ABOUT THE THREE PREVIOUS MOVIES
EVANGELION:1.11 YOU ARE (NOT) ALONE.
Scarred by the Second Impact, the Fourth Angel attacks Tokyo III and humanity's fate is left in the hands of Special Government Agency Nerv. Young Shinji Ikari is forced to pilot EVA-01. He and EVA-00 pilot Rei Ayanami are tasked to fight, but EVA-01 is damaged by the Sixth Angel. Misato Katsuragi draws up a plan to focus all of Japan's electricity into EVA-01's positron cannon to defeat the Angel.
Studio: khara, Inc.
Chief director: Hideaki Anno
, Director: Masayuki
and Kazuya Tsurumaki
, Screenwriter: Hideaki Anno
EVANGELION:2.22 YOU CAN (NOT) ADVANCE.
Mari Illustrious-Makinami pilots Provisional Unit-05 to defeat the excavated Third Angel. Asuka Langley-Shikinami and EVA-02 defeat the Seventh Angel. The Eighth Angel appears and attacks Nerv HQ. EVA-03 is taken over by the Ninth Angel during testing and Shinji deploys to stop it, but learns Asuka is aboard. Gendo switches EVA-01's controls over to the Dummy System and begins fighting EVA-03.
Studio: khara, Inc.
Chief director: Hideaki Anno
, Director: Masayuki
and Kazuya Tsurumaki
, Screenwriter: Hideaki Anno
EVANGELION:3.33 YOU CAN (NOT) REDO.
Shinji wakes after 14 years aboard the battleship AAA Wunder belonging to an anti-Nerv organization founded by former Nerv members. Shinji hears Rei's voice coming from EVA Mark.09, sent to rescue him, so he leaves Wunder and heads to Nerv. Kaworu Nagisa shows Shinji the transformed land. He learns that saving Rei triggered the Near Third Impact that caused the catastrophic damage to Earth.
Studio: khara, Inc.
Chief director: Hideaki Anno
, Director: Masayuki
, Mahiro Maeda
and Kazuya Tsurumaki
, Screenwriter: Hideaki Anno
EVANGELION:3.0+1.01 THRICE UPON A TIME will join the thousands of TV shows and movies in the Prime Video catalogue, including award-winning and critically acclaimed global Amazon Originals like Borat Subsequent Moviefilm, Tom Clancy's Jack Ryan, The Boys, Hunters, Fleabag, and The Marvelous Mrs. Maisel. All this is available on Prime Video at no extra cost for Prime members. Prime members will be able to watch EVANGELION:3.0+1.01 THRICE UPON A TIME anywhere and anytime on the Prime Video app for smart TVs, mobile devices, Fire TV, Fire TV stick, Fire tablets, Apple TV, and stream online. In the Prime Video app, Prime members can download episodes on their mobile devices and tablets and watch anywhere offline.
Amazon
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005692/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release
Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
